Evidence map›Paper›PMID 37698037›Full record

ArticleJournal of cellular and molecular medicine2023

Inhibitory role of bone marrow mesenchymal stem cells-derived exosome in non-small-cell lung cancer: microRNA-30b-5p, EZH2 and PI3K/AKT pathway.

Tong Wu, Qi Tian, Ruiji Liu, Ke Xu, Shanshan Shi, Xiudi Zhang, Liming Gao, Xiaobo Yin, Shufeng Xu, Ping Wang

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors.Medical oncology (Northwood, London, England) · 2024
    Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Tong WuGraduate School of Zunyi Medical University, Zunyi, China.
Qi TianDepartment of Pulmonary and Critical Care Medicine, The First Hospital of Qinhuangdao, Qinhuangdao, China.
Ruiji LiuDepartment of Pulmonary and Critical Care Medicine, The First Hospital of Qinhuangdao, Qinhuangdao, China.
Ke XuGraduate School of Hebei Medical University, Shijiazhuang, China.
Shanshan ShiDepartment of Pulmonary and Critical Care Medicine, The First Hospital of Qinhuangdao, Qinhuangdao, China.
Xiudi ZhangGraduate School of Hebei Medical University, Shijiazhuang, China.
Liming GaoOncology Department, The First Hospital of Qinhuangdao, Qinhuangdao, China.
Xiaobo YinDepartment of Pulmonary and Critical Care Medicine, The First Hospital of Qinhuangdao, Qinhuangdao, China.
Shufeng XuDepartment of Pulmonary and Critical Care Medicine, The First Hospital of Qinhuangdao, Qinhuangdao, China.ORCID 0000-0003-3823-610X
Ping WangDepartment of Pulmonary and Critical Care Medicine, Chinese People's Liberation Army General Hospital, Beijing, China.
First Hospital of Qinhuangdao · CNHebei Medical University · CNChinese General Hospital College of Nursing and Liberal Arts · PHZunyi Medical University · CN

Funding

Natural Science Foundation of Hebei Province H2021107002
6 · The paper itself

Abstract

Exosomal microRNA (miRNA) exerts potential roles in non-small-cell lung cancer (NSCLC). The current study elucidated the role of miR-30b-5p shuttled by bone marrow mesenchymal stem cells (BMSCs)-derived exosomes in treating NSCLC. Bioinformatics analysis was performed with NSCLC-related miRNA microarray GSE169587 and mRNA data GSE74706 obtained for collection of the differentially expressed miRNAs and mRNAs. The relationship between miR-30b-5p and EZH2 was predicted and confirmed. Exosomes were isolated from BMSCs and identified. BMSCs-derived exosomes overexpressing miR-30b-5p were used to establish subcutaneous tumorigenesis models to study the effects of miR-30b-5p, EZH2 and PI3K/AKT signalling pathway on tumour growth. A total of 86 BMSC-exo-miRNAs were differentially expressed in NSCLC. Bioinfomatics analysis found that BMSC-exo-miR-30b-5p could regulate NSCLC progression by targeting EZH2, which was verified by in vitro cell experiments. Besides, the target genes of miR-30b-5p were enriched in PI3K/AKT signalling pathway. Animal experiments validated that BMSC-exo-miR-30b-5p promoted NSCLC cell apoptosis and prevented tumorigenesis in nude mice via EZH2/PI3K/AKT axis. Collectively, the inhibitory role of BMSC-derived exosomes-loaded miR-30b-5p in NSCLC was achieved through blocking the EZH2/PI3K/AKT axis.

Indexed as

Carcinoma, Non-Small-Cell LungExosomesLung NeoplasmsMesenchymal Stem CellsMicroRNAsAnimalsCarcinogenesisMiceMice, NudePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktMicroRNAsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktbone marrow mesenchymal stem cellsexosomeEZH2microRNA-30b-5pnon-small-cell lung cancerPI3K/AKT

Identifiers

PMID37698037
PMCPMC10660609
OpenAlexW4386624378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.